Heron Therapeutics, Inc. (0J4V.L)
USD 2.4
(0.42%)
USD 2.4
(0.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 10.04 Million USD | -80.98% |
| 2022 | 52.79 Million USD | 30.93% |
| 2021 | 40.32 Million USD | -23.12% |
| 2020 | 52.44 Million USD | -37.82% |
| 2019 | 84.34 Million USD | 68.83% |
| 2018 | 49.96 Million USD | 90.85% |
| 2017 | 26.17 Million USD | 17954.48% |
| 2016 | 145 Thousand USD | 119.75% |
| 2015 | -734 Thousand USD | 98.66% |
| 2014 | -54.83 Million USD | -77.36% |
| 2013 | -30.91 Million USD | -119.65% |
| 2012 | -14.07 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 26.22 Million USD | 7.71% |
| 2024 Q2 | 24.95 Million USD | -4.85% |
| 2023 Q1 | 12.76 Million USD | -26.67% |
| 2023 Q3 | 13.22 Million USD | 13.98% |
| 2023 Q4 | 24.34 Million USD | 84.09% |
| 2023 FY | 61.93 Million USD | 17.31% |
| 2023 Q2 | 11.6 Million USD | -9.07% |
| 2022 FY | 52.79 Million USD | 30.93% |
| 2022 Q3 | 11.84 Million USD | 3.36% |
| 2022 Q2 | 11.45 Million USD | -5.35% |
| 2022 Q1 | 12.1 Million USD | 24.58% |
| 2022 Q4 | 17.4 Million USD | 46.97% |
| 2021 Q4 | 9.71 Million USD | -18.23% |
| 2021 Q2 | 7.92 Million USD | -26.73% |
| 2021 Q3 | 11.87 Million USD | 49.97% |
| 2021 FY | 40.32 Million USD | -23.12% |
| 2021 Q1 | 10.81 Million USD | 133.74% |
| 2020 Q3 | -36.38 Million USD | -19.93% |
| 2020 Q4 | -32.04 Million USD | 11.95% |
| 2020 FY | 52.44 Million USD | -37.82% |
| 2020 Q1 | -22.11 Million USD | 23.92% |
| 2020 Q2 | -30.34 Million USD | -37.19% |
| 2019 Q1 | -26.33 Million USD | -26.48% |
| 2019 Q2 | -18.35 Million USD | 30.3% |
| 2019 Q4 | -29.06 Million USD | -213.27% |
| 2019 FY | 84.34 Million USD | 68.83% |
| 2019 Q3 | -9.27 Million USD | 49.44% |
| 2018 FY | 49.96 Million USD | 90.85% |
| 2018 Q4 | -20.81 Million USD | -14.32% |
| 2018 Q3 | -18.21 Million USD | -0.54% |
| 2018 Q2 | -18.11 Million USD | 41.81% |
| 2018 Q1 | -31.12 Million USD | 20.27% |
| 2017 FY | 26.17 Million USD | 17954.48% |
| 2017 Q2 | -21.1 Million USD | 31.8% |
| 2017 Q3 | -21.32 Million USD | -1.06% |
| 2017 Q4 | -39.04 Million USD | -83.1% |
| 2017 Q1 | -30.93 Million USD | -28.05% |
| 2016 Q3 | -30.24 Million USD | -10.83% |
| 2016 FY | 145 Thousand USD | 119.75% |
| 2016 Q2 | -27.28 Million USD | -69.56% |
| 2016 Q1 | -16.09 Million USD | 1.05% |
| 2016 Q4 | -24.16 Million USD | 20.11% |
| 2015 FY | -734 Thousand USD | 98.66% |
| 2015 Q4 | -16.26 Million USD | -14.2% |
| 2015 Q1 | -14.5 Million USD | -16.23% |
| 2015 Q3 | -14.24 Million USD | 11.96% |
| 2015 Q2 | -16.17 Million USD | -11.52% |
| 2014 Q2 | -14.27 Million USD | -22.8% |
| 2014 Q3 | -14.73 Million USD | -3.17% |
| 2014 FY | -54.83 Million USD | -77.36% |
| 2014 Q1 | -11.62 Million USD | -72.16% |
| 2014 Q4 | -12.47 Million USD | 15.29% |
| 2013 FY | -30.91 Million USD | -119.65% |
| 2013 Q4 | -6.75 Million USD | -8.66% |
| 2013 Q1 | -7.14 Million USD | -38.59% |
| 2013 Q3 | -6.21 Million USD | 42.48% |
| 2013 Q2 | -10.8 Million USD | -51.34% |
| 2012 Q4 | -5.15 Million USD | 0.0% |
| 2012 FY | -14.07 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -353.363% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -3225.166% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 111.784% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 42.017% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 3308.307% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 32.121% |
| Imunon, Inc. | -720 Thousand USD | 1494.713% |
| Dynavax Technologies Corporation | 182.11 Million USD | 94.486% |
| Editas Medicine, Inc. | -99.52 Million USD | 110.09% |
| FibroGen, Inc. | 128.9 Million USD | 92.21% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 204.976% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 3414.191% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.456% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.081% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.083% |
| Verastem, Inc. | -62 Thousand USD | 16296.774% |
| Zoetis Inc. | 5.83 Billion USD | 99.828% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.883% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 122.156% |
| Homology Medicines, Inc. | -7.22 Million USD | 238.913% |
| Nektar Therapeutics | 53.47 Million USD | 81.222% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 3539.041% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 150.977% |
| Perrigo Company plc | 1.68 Billion USD | 99.402% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 86.256% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.962% |
| Illumina, Inc. | 2.74 Billion USD | 99.634% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.934% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 99.808% |
| Waters Corporation | 1.76 Billion USD | 99.43% |
| Biogen Inc. | 7.3 Billion USD | 99.862% |
| Evolus, Inc. | 140.52 Million USD | 92.854% |
| Adicet Bio, Inc. | -6.09 Million USD | 264.677% |
| bluebird bio, Inc. | -4.03 Million USD | 349.181% |
| Geron Corporation | -123.5 Million USD | 108.131% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.338% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 97.226% |
| Myriad Genetics, Inc. | 476.4 Million USD | 97.892% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 102.518% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.537% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 132.219% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.473% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.911% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 99.71% |
| OPKO Health, Inc. | 318.12 Million USD | 96.843% |
| Exelixis, Inc. | 1.75 Billion USD | 99.429% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 97.89% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 95.893% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 98.71% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 98.423% |
| Blueprint Medicines Corporation | 236.58 Million USD | 95.755% |
| Insmed Incorporated | 239.63 Million USD | 95.809% |
| TG Therapeutics, Inc. | 219.1 Million USD | 95.417% |
| Incyte Corporation | 3.44 Billion USD | 99.708% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 97.08% |